134 results on '"De Vincenzo F."'
Search Results
2. Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma
3. Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma
4. Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial
5. Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma
6. Health professionals and students’ experiences of reflective writing in learning: A qualitative meta-synthesis
7. Psychophysiological adjustment in ovarian cancer survivors: A correlational study
8. Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
9. F21When the time matters: Metastatic Castration Resistant Prostate Cancer (mCRPC) patients long responders to Abiraterone acetate (AA) in post-docetaxel setting
10. When the time matters: Metastatic Castration Resistant Prostate Cancer (mCRPC) patients long responders to Abiraterone acetate (AA) in post-docetaxel setting
11. Vinorelbine as second or third-line therapy in pemetrexed-pretreated malignant pleural mesothelioma (MPM) patients
12. Tivantinib in combination with Carboplatin and Pemetrexed as first line treatment in patients with advanced non-squamous NSCLC or Malignant Pleural Mesothelioma: results of phase I trial
13. Non-small-cell lung cancer patients unsuitable for first-line chemotherapy: A new category of patients for clinical studies?
14. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma
15. Il ruolo dell'ormonoterapia nel carcinoma della mammella in eta' geriatrica
16. Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
17. Reproducibility of the WHO classification of thymomas: Practical implications
18. Phase I and pharmacodynamic study of high-dose NGR–hTNF in patients with refractory solid tumours
19. O5 Progression free survival (PFS) and overall survival (OS) in patients receiving 3 targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC)
20. Impact of Soluble Tumor Necrosis Factor-Receptors (STNF-RS) Shedding on Outcome in PAtients Treated With Ngr-Htnf
21. Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey
22. Advances in the biology of malignant pleural mesothelioma
23. 1205 ORAL Phase I and Pharmacodynamic Study of High-dose NGR-hTNF in Patients With Refractory Solid Tumours
24. 1247 POSTER Phase I, Pharmacokinetics (PK), Pharmacodynamic (PD) Study of Lapatinib (L) in Combination With Sorafenib (S) in Patients With Advanced Refractory Solid Tumours
25. Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors.
26. Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors.
27. NGR-hTNF in previously treated patients with malignant pleural mesothelioma (MPM) .
28. Vinorelbine (V) in pemetrexed-pretreated patients (PTS) with malignant pleural mesothelioma (MPM).
29. Phase I study of NGR-hTNF administered at high doses in refractory patients with solid tumors.
30. Different toxicity profile of sorafenib across various types of cancer.
31. Retreatment with pemetrexed-based chemotherapy (PBC) in patients with malignant pleural mesothelioma (MPM): An observational study.
32. The Role of Pemetrexed in the Pharmacotherapy of Malignant Pleural Mesothelioma
33. 9127 The role of thymidylate synthase (TS) and excision repair cross-complementing group 1 (ERCC1) immunohistochemical expression in malignant pleural mesothelioma patients treated with pemetrexed and carboplatin
34. Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas
35. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
36. 80 Early response evaluation in malignant pleural mesothelioma by positron emission tomography with 18F-fluorodeoxyglucose
37. 201 Treatment with gemcitabine and vinorelbine (GEMVIN) as second-line chemotherapy in pemetrexed-pretreated patients with malignant pleural mesothelioma (MPM)
38. P-394 Positron emission tomography with F18-fluorodeoxyglucose (FDG-PET) in malignant pleural mesothelioma (MPM): Prediction of response to chemotheraphy by quantitative assessment of standard uptake value (SUV)
39. Short-schedule cisplatin and vinorelbine as induction chemotherapy in stage IIIA(N2)-IIIB non small cell lung cancer (NSCLC)
40. Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with refractory solid tumours.
41. Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma.
42. Non-small-cell lung cancer patients unsuitable for first-line chemotherapy: a new category of patients for clinical studies?
43. Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial
44. Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma
45. Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy
46. Phase I and pharmacodynamic study of high-dose NGR–hTNF in patients with refractory solid tumours
47. Phase II Study of Asparagine-Glycine-Arginine–Human Tumor Necrosis Factor α, a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma
48. La legge rango-dimensione quale metodologia preliminare all'analisi della resilienza.Il caso del litorale austro-illirico
49. LA SHADOW ECONOMY: RESILIENZA O CONVENIENZA? L’ITALIA NELLA DIMENSIONE EUROPEA
50. Mercato globale e valute regionali. Un equilibrio conflittuale
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.